A combination of a PPAR-γ agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells

Clinical Nephrology

Volumn 68, Issue 5, 2007, Pages 295-301

  Yao, Q ^a,b   Rodriguez Ayala E ^a,c   Qian, J Q ^b   Stenvinkel, P ^a   Axelsson, J ^a   Lindholm, Beng ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Hospital Regional IMSS   (Mexico)

Author keywords

AT1 receptor blocker; Cytokine; High glucose; PPAR agonist; TGF Smad7

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; GLUCOSE; INTERLEUKIN 6; INTERLEUKIN 8; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MESOTHELIUM CELL; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; EPITHELIUM; GLUCOSE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LOSARTAN; PERITONEUM; PPAR GAMMA; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35748953774     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A et al. A mechanism of suppression of TGF-β/SMAD signaling by NF-κ B/RelA. Genes Dev. 2000; 14: 187-197.
2. Bottinger EP, Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol. 2002; 13: 2600-2610.
3. Chawla A, Barak Y, Nagy L, Liao D et al. PPAR-γ-dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001; 7: 48-52.
4. 1/Smads in the development of peritoneal fibrosis induced by high glucose peritoneal dialysate and LPS. Zhonghua Yi Xue Za Zhi. 2005; 85: 2613-2618.
5. Duman S, Gunal AI, Sen S, Asci G et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int. 2001; 21: 219-224.
6. Fauconnet S, Lascombe I, Chabannes E, Adessi GL et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem. 2002; 277: 23534-23543.
7. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ et al. Disruption of transforming growth factor-β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor-γ. Arthritis Rheum. 2004; 50: 1305-1318.
8. Groneberg DA, Witt H, Adcock IM, Hansen G et al. Smads as intracellular mediators of airway inflammation. Exp Lung Res. 2004; 30: 223-250.
9. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002; 22: 171-177.
10. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-β1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int. 2001; 59: 463-470.
11. Haslinger B, Kleemann R, Toet KH, Kooistra T. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-α-activated human peritoneal mesothelial cells. Kidney Int. 2003; 63: 2065-2074.
12. Hattori Y, Akimoto K, Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun. 2000; 273: 1144-1149.
13. Hung KY, Shyu RS, Fang CC, Tsai CC et al. Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int. 2001; 59: 2316-2324.
14. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391: 82-86.
15. Jozkowicz A, Dulak J, Prager M, Nanobashvili J et al. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-γ-independent manner. Prostaglandins Other Lipid Mediat. 2001; 66: 165-177.
16. 1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int. 2005; 25: 483-491.
17. Li JH, Huang XR, Zhu HJ, Johnson R et al. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003; 63: 2010-2019.
18. Liao J, Kobayashi M, Kanamuru Y, Nakamura S et al. Effects of candesartan, an angiotensin II Type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol. 2003; 16: 841-849.
19. 1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004; 64: 4405-4410.
20. Mix KS, Coon CI, Rosen ED, Suh N et al. Peroxisome proliferator-activated receptor-γ-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-δ (12,14) J2: a role for Smad signaling. Mol Pharmacol. 2004; 65: 309-318.
21. Noh H, Kim JS, Han KH, Lee GT et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int. 2006; 69: 2022-2028.
22. 1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005; 25: 38-47.
23. Ricote M, Li AC, Willson TM, Kelly CJ et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998; 391: 79-82.
24. Takeda K, Ichiki T, Tokunou T, Funakoshi Y et al. Peroxisome proliferator-activated receptor-γ activators downregulate angiotensin II Type 1 receptor in vascular smooth muscle cells. Circulation. 2000; 102: 1834-1839.
25. Tang SC, Leung JC, Chan LY, Tsang AW et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-γ agonist. J Am Soc Nephrol. 2006; 17: 1633-1643.
26. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature. 1999; 397: 710-713.
27. 1 promoter activation: similarity to hyperglycaemia. Diabetologia. 2002; 45: 890-898.
28. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H et al. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats. Perit Dial Int. 2001; 21 (Suppl 3): 108-113.
29. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant. 2004; 19: 917-924.
30. Yao Q, Pawlaczyk K, Rodriguez Ayala E, Styszynski A et al. PPAR-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. Blood Purif. 2006; in press.
31. Yao Q, Qian JQ, Lin XH, Lindholm B. Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells. Int J Artif Organs 2004; 27: 828-834.
32. Yoshimura A, Mori H, Ohishi M, Aki D et al. Negative regulation of cytokine signaling influences inflammation. Curr Opin Immunol. 2003; 15: 704-708.
33. Zheng F, Fornoni A, Elliot SJ, Guan Y et al. Upregulation of Type I collagen by TGF-β in mesangial cells is blocked by PPAR-γ activation. Am J Physiol Ren Physiol. 2002; 282: F639-648.